UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average burden						
hours per response	0.5					

longer subject to Section 16. Form 4 or Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	e Responses	s)													
Name and Address of Reporting Person* Noble James					2. Issuer Name and Ticker or Trading Symbol Adaptimmune Therapeutics PLC [ADAP]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director				
BROCK HOUSE, SHEEPDROVE, LAMBOURN				3. Date of Earliest Transaction (Month/Day/Year) 01/12/2018						X_ Officer (give title below) Other (specify below) Chief Executive Officer					
(Street) HUNGERFORD, X0 RG17 7XA			4. If A	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
HUNGEI (Cit		(State)	(Zip)		Table I - Non-Derivative Securities Acou						ired, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye		2A. Deemed Execution Date, if Code (Instr. (Month/Day/Year)		Tran	asaction 4. (A	Securities Acq	ccurities Acquired or Disposed of (D) r. 3, 4 and 5) (A) or 5. Am Owned Transa (Instr.		Amount of Securities Beneficially and Following Reported unsaction(s) str. 3 and 4)		ownership orm:	Seneficial Ownership			
Reminder: 1	Report on a s	eparate line for each	class of securities b					Persons this forr currently	who respond n are not requ y valid OMB of sed of, or Bene	uired to re control nu	spond unles mber.			n SEC 14	174 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		Execution Date, if	4. Transaction Code		5. Number of		options, convertible securi 6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported	10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Nature of Indirec Beneficia Ownershi (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s (Instr. 4)	(I) (Instr. 4)	
Option to purchase Ordinary Shares	\$ 1.3 (1)	01/12/2018		A		1,719,936		(2)	01/12/2028	Ordinary Shares	1,719,936	\$ 0	1,719,936	D	
Option to purchase Ordinary Shares	\$ 0.0014	01/12/2018		A		384,120		<u>(4)</u>	01/12/2028	Ordinary Shares	384,120	\$ 0	384,120	D	

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Noble James BROCK HOUSE, SHEEPDROVE, LAMBOURN HUNGERFORD, X0 RG17 7XA	X		Chief Executive Officer				

Signatures

/s/ James Noble	01/17/2018
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The exercise price was converted from GBP0.96 based on an exchange rate of \$U.S. 1.3542 GBP1.00. The actual exercise price will be the pounds sterling amount.

- Exercisable as to 429,984 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in monthly installments of 35,832 Ordinary Shares on the twelfth of each month from February 12, 2019 through January 12, 2022.
- The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of \$U.S. 1.3542 GBP1.00. The actual exercise price will be the pounds sterling amount.
- (4) Exercisable as to 96,030 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in annual installments of 96,030 Ordinary Shares on the twelfth of each January from January 12, 2020 through January 12, 2022.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.